JP2017538446A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538446A5 JP2017538446A5 JP2017547931A JP2017547931A JP2017538446A5 JP 2017538446 A5 JP2017538446 A5 JP 2017538446A5 JP 2017547931 A JP2017547931 A JP 2017547931A JP 2017547931 A JP2017547931 A JP 2017547931A JP 2017538446 A5 JP2017538446 A5 JP 2017538446A5
- Authority
- JP
- Japan
- Prior art keywords
- recombinant protein
- perfusion
- mammalian host
- bioreactor
- culture medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 26
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 14
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 14
- 230000010412 perfusion Effects 0.000 claims 7
- 239000006143 cell culture medium Substances 0.000 claims 5
- 150000004676 glycans Chemical class 0.000 claims 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 2
- 229910052802 copper Inorganic materials 0.000 claims 2
- 239000010949 copper Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 229910052748 manganese Inorganic materials 0.000 claims 2
- 239000011572 manganese Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 230000003698 anagen phase Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 238000003306 harvesting Methods 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 230000000630 rising effect Effects 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462085759P | 2014-12-01 | 2014-12-01 | |
| US62/085,759 | 2014-12-01 | ||
| PCT/US2015/063271 WO2016089919A1 (en) | 2014-12-01 | 2015-12-01 | Process for manipulating the level of glycan content of a glycoprotein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020080270A Division JP7066775B2 (ja) | 2014-12-01 | 2020-04-30 | 糖タンパク質のグリカン含量のレベルを操作するためのプロセス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017538446A JP2017538446A (ja) | 2017-12-28 |
| JP2017538446A5 true JP2017538446A5 (OSRAM) | 2019-01-17 |
| JP6698681B2 JP6698681B2 (ja) | 2020-05-27 |
Family
ID=55024253
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017547931A Active JP6698681B2 (ja) | 2014-12-01 | 2015-12-01 | 糖タンパク質のグリカン含量のレベルを操作するためのプロセス |
| JP2020080270A Active JP7066775B2 (ja) | 2014-12-01 | 2020-04-30 | 糖タンパク質のグリカン含量のレベルを操作するためのプロセス |
| JP2022072126A Pending JP2022101669A (ja) | 2014-12-01 | 2022-04-26 | 糖タンパク質のグリカン含量のレベルを操作するためのプロセス |
| JP2024063188A Pending JP2024095777A (ja) | 2014-12-01 | 2024-04-10 | 糖タンパク質のグリカン含量のレベルを操作するためのプロセス |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020080270A Active JP7066775B2 (ja) | 2014-12-01 | 2020-04-30 | 糖タンパク質のグリカン含量のレベルを操作するためのプロセス |
| JP2022072126A Pending JP2022101669A (ja) | 2014-12-01 | 2022-04-26 | 糖タンパク質のグリカン含量のレベルを操作するためのプロセス |
| JP2024063188A Pending JP2024095777A (ja) | 2014-12-01 | 2024-04-10 | 糖タンパク質のグリカン含量のレベルを操作するためのプロセス |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US10167492B2 (OSRAM) |
| EP (2) | EP3680344A1 (OSRAM) |
| JP (4) | JP6698681B2 (OSRAM) |
| KR (1) | KR102623965B1 (OSRAM) |
| CN (1) | CN107109455B (OSRAM) |
| AU (5) | AU2015355087C1 (OSRAM) |
| CA (1) | CA2969225C (OSRAM) |
| CL (1) | CL2017001369A1 (OSRAM) |
| CY (1) | CY1123247T1 (OSRAM) |
| DK (1) | DK3227454T3 (OSRAM) |
| EA (2) | EA202091598A3 (OSRAM) |
| ES (1) | ES2784503T3 (OSRAM) |
| HU (1) | HUE049201T2 (OSRAM) |
| IL (2) | IL276165B (OSRAM) |
| LT (1) | LT3227454T (OSRAM) |
| MX (1) | MX385409B (OSRAM) |
| PL (1) | PL3227454T3 (OSRAM) |
| PT (1) | PT3227454T (OSRAM) |
| SG (2) | SG10202002458PA (OSRAM) |
| SI (1) | SI3227454T1 (OSRAM) |
| WO (1) | WO2016089919A1 (OSRAM) |
| ZA (2) | ZA201703729B (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3227454T (lt) | 2014-12-01 | 2020-07-27 | Amgen Inc. | Glikoproteino glikano sudedamosios dalies kiekio keitimo procedūra |
| EP3397282A4 (en) | 2015-12-30 | 2019-08-07 | Momenta Pharmaceuticals, Inc. | METHODS RELATING TO BIOLOGICA |
| AU2018235928B2 (en) * | 2017-03-14 | 2023-09-21 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
| KR102604988B1 (ko) * | 2017-03-31 | 2023-11-24 | 베링거 인겔하임 인터내셔날 게엠베하 | 관류 배지 |
| CN111373028B (zh) * | 2017-11-30 | 2022-07-05 | 正大天晴药业集团南京顺欣制药有限公司 | 蛋白质的生产方法 |
| MX2020009907A (es) * | 2018-03-26 | 2020-10-14 | Amgen Inc | Glicoformas afucosiladas totales de anticuerpos producidos en cultivo celular. |
| EP3802846A1 (en) * | 2018-05-24 | 2021-04-14 | Ares Trading S.A. | Method for controlling the afucosylation level of a glycoprotein composition |
| MX2020013036A (es) | 2018-06-05 | 2021-02-26 | Amgen Inc | Modulacion de la fagocitosis celular dependiente de anticuerpos. |
| CA3110530A1 (en) | 2018-09-11 | 2020-03-19 | Amgen Inc. | Methods of modulating antibody-dependent cell-mediated cytotoxicity |
| HU231514B1 (hu) * | 2018-11-07 | 2024-07-28 | Richter Gedeon Nyrt. | Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer |
| EP3880824B1 (en) | 2018-11-13 | 2024-07-24 | Janssen Biotech, Inc. | Control of trace metals during production of anti-cd38 antibodies |
| US20220081479A1 (en) * | 2018-12-31 | 2022-03-17 | Momenta Pharmaceuticals, Inc. | Methods of producing ustekinumab |
| SG11202107762QA (en) * | 2019-01-30 | 2021-08-30 | Amgen Inc | Aflibercept attributes and methods of characterizing and modifying thereof |
| MX2021013628A (es) | 2019-05-06 | 2022-03-07 | Amgen Inc | Modulación de las funciones efectoras de anticuerpos. |
| JP2020188737A (ja) * | 2019-05-23 | 2020-11-26 | 東ソー株式会社 | 抗体依存性細胞傷害活性が向上した抗体の製造方法 |
| CN114450593A (zh) | 2019-09-26 | 2022-05-06 | 美国安进公司 | 产生抗体组合物的方法 |
| WO2022026451A1 (en) * | 2020-07-30 | 2022-02-03 | Amgen Inc. | Cell culture media and methods of making and using the same |
| US20230313259A1 (en) * | 2020-08-14 | 2023-10-05 | Bristol-Myers Squibb Company | Manufacturing process for protein |
| WO2022081824A1 (en) | 2020-10-15 | 2022-04-21 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
| CA3222409A1 (en) | 2021-06-07 | 2022-12-15 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
| WO2023161885A1 (en) * | 2022-02-25 | 2023-08-31 | Kashiv Biosciences, Llc | A process for improving polypeptide expression in mammalian cell culture |
| AU2024256160A1 (en) | 2023-04-20 | 2025-10-02 | Amgen Inc. | Methods of determining relative unpaired glycan content |
| WO2025036924A1 (en) * | 2023-08-16 | 2025-02-20 | Glaxosmithkline Intellectual Property Limited | Method of controlling antibody glycosylation profile |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| AU588819B2 (en) | 1984-10-29 | 1989-09-28 | Immunex Corporation | Cloning of human granulocyte-macrophage colony stimulating factor gene |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
| US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| EP0417563B1 (de) | 1989-09-12 | 2000-07-05 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
| US6204363B1 (en) | 1989-10-16 | 2001-03-20 | Amgen Inc. | Stem cell factor |
| US5149792A (en) | 1989-12-19 | 1992-09-22 | Amgen Inc. | Platelet-derived growth factor B chain analogs |
| US5272064A (en) | 1989-12-19 | 1993-12-21 | Amgen Inc. | DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof |
| AU651596B2 (en) | 1990-06-05 | 1994-07-28 | Immunex Corporation | Type II interleukin-1 receptors |
| US5096816A (en) | 1990-06-05 | 1992-03-17 | Cetus Corporation | In vitro management of ammonia's effect on glycosylation of cell products through pH control |
| US5350683A (en) | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
| US6284471B1 (en) * | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
| ES2198414T3 (es) | 1992-10-23 | 2004-02-01 | Immunex Corporation | Procedimientos para preparar proteinas oligomericas solubles. |
| US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
| US5981713A (en) | 1994-10-13 | 1999-11-09 | Applied Research Systems Ars Holding N.V. | Antibodies to intereleukin-1 antagonists |
| US5721121A (en) | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
| DK1666591T3 (da) | 1995-06-29 | 2011-05-23 | Immunex Corp | Cytokin der inducerer apoptose |
| US6613544B1 (en) | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
| US6096728A (en) | 1996-02-09 | 2000-08-01 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| US6271349B1 (en) | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6337072B1 (en) | 1998-04-03 | 2002-01-08 | Hyseq, Inc. | Interleukin-1 receptor antagonist and recombinant production thereof |
| US6528286B1 (en) | 1998-05-29 | 2003-03-04 | Genentech, Inc. | Mammalian cell culture process for producing glycoproteins |
| JP2001120262A (ja) | 1999-10-26 | 2001-05-08 | Welfide Corp | 生理活性物質の産生増強方法 |
| WO2001036637A1 (en) | 1999-11-17 | 2001-05-25 | Immunex Corporation | Receptor activator of nf-kappa b |
| US6544424B1 (en) | 1999-12-03 | 2003-04-08 | Refined Technology Company | Fluid filtration system |
| SI1248802T1 (en) | 2000-05-26 | 2005-02-28 | Bristol-Myers Squibb Co. | Soluble ctla4 mutant molecules and uses thereof |
| US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
| DE10312765A1 (de) | 2003-03-21 | 2004-09-30 | Bayer Technology Services Gmbh | Vorrichtung und Verfahren zur Sterilisation flüssiger Medien mittels UV-Bestrahlung und Kurzzeiterhitzung |
| TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
| TWI364458B (en) * | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
| US8053238B2 (en) | 2005-10-31 | 2011-11-08 | Unhwa Corporation | Isolated population of plant single cells and method of preparing the same |
| US20070231895A1 (en) | 2005-11-02 | 2007-10-04 | Lee Gene W | Methods for adapting mammalian cells |
| AU2006324163B2 (en) | 2005-12-08 | 2013-05-02 | Amgen Inc. | Improved production of glycoproteins using manganese |
| WO2007081031A1 (ja) * | 2006-01-16 | 2007-07-19 | Hokkaido University | 糖転移酵素阻害剤 |
| ES2668212T3 (es) | 2006-07-13 | 2018-05-17 | Wyeth Llc | Producción de factor de coagulación IX con patrón de glucosilación mejorado |
| US20100166741A1 (en) * | 2006-07-13 | 2010-07-01 | Genentech , Inc. | Altered br-3 binding polypeptides |
| FR2904558B1 (fr) * | 2006-08-01 | 2008-10-17 | Lab Francais Du Fractionnement | "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees" |
| EP2395077A1 (en) | 2006-11-03 | 2011-12-14 | Wyeth LLC | Glycolysis-inhibiting substances in cell culture |
| CA2679941C (en) | 2007-03-02 | 2016-09-20 | Wyeth | Use of copper and glutamate in cell culture for production of polypeptides |
| WO2008121757A1 (en) * | 2007-03-30 | 2008-10-09 | Centocor Inc | High expression clones of mammalian cells with fluorescent protein a or g |
| RU2009141965A (ru) | 2007-04-16 | 2011-05-27 | Момента Фармасьютикалз, Инк. (Us) | Определенные продукты гликопротеина и способы их производства |
| US20100221823A1 (en) | 2007-06-11 | 2010-09-02 | Amgen Inc. | Method for culturing mammalian cells to improve recombinant protein production |
| EP2173861B2 (en) | 2007-06-15 | 2017-02-22 | Amgen Inc. | Methods of treating cell culture media for use in a bioreactor |
| EP2438185A4 (en) | 2009-06-05 | 2016-10-05 | Momenta Pharmaceuticals Inc | METHODS FOR MODULATING FUCOSYLATION OF GLYCOPROTEINS |
| RU2013122843A (ru) | 2010-10-20 | 2014-11-27 | Морфотек, Инк. | Гликоформы антитела против фолатного рецептора альфа |
| KR20130129438A (ko) | 2011-02-23 | 2013-11-28 | 암젠 인크 | Uvc 노출을 위한 세포 배양 배지 및 이와 관련된 방법 |
| AU2012226398B9 (en) * | 2011-03-06 | 2017-04-13 | Merck Serono S.A. | Low fucose cell lines and uses thereof |
| WO2012145682A1 (en) | 2011-04-21 | 2012-10-26 | Amgen Inc. | A method for culturing mammalian cells to improve recombinant protein production |
| EP2702077A2 (en) * | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| KR102558247B1 (ko) | 2011-07-01 | 2023-07-24 | 암젠 인크 | 포유동물 세포 배양 |
| AR087433A1 (es) * | 2011-08-08 | 2014-03-26 | Merck Sharp & Dohme | Analogos de insulina n-glicosilados |
| CN103946366B (zh) | 2011-09-16 | 2017-08-11 | 安姆根有限公司 | 细胞培养物的预编程非反馈控制的连续供料 |
| ES2693508T3 (es) | 2011-10-26 | 2018-12-12 | Amgen Inc. | Métodos para reducir o eliminar la modificación y la degradación de proteínas debidas a una exposición a luz UV |
| CN104487570A (zh) * | 2012-01-20 | 2015-04-01 | 新加坡科技研究局 | Cho-gmt重组蛋白的表达 |
| WO2013114164A1 (en) * | 2012-01-30 | 2013-08-08 | Dr. Reddy's Laboratories Limited | Method for obtaining glycoprotein composition with increased afucosylation content |
| US10059770B2 (en) | 2012-01-30 | 2018-08-28 | Dr. Reddy's Laboratories Limited | Process of modulating man5 and/or afucosylation content of a glycoprotein composition |
| WO2013138159A1 (en) | 2012-03-15 | 2013-09-19 | Amgen Inc. | Methods of determining exposure to uv light |
| US10481164B2 (en) | 2012-03-26 | 2019-11-19 | Amgen Inc. | Method for using light scattering in real time to directly monitor and control impurity removal in purification processes |
| JP6273205B2 (ja) * | 2012-10-05 | 2018-01-31 | 協和発酵キリン株式会社 | ヘテロダイマータンパク質組成物 |
| US8956830B2 (en) | 2013-03-14 | 2015-02-17 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| US9677105B2 (en) | 2013-03-14 | 2017-06-13 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| JP6480926B2 (ja) | 2013-07-23 | 2019-03-13 | バイオコン・リミテッド | タンパク質におけるフコシル化レベルを制御するための方法 |
| DK3110961T3 (da) | 2014-02-27 | 2020-02-03 | Hoffmann La Roche | Modulering af cellevækst og glycosylering i rekombinant glycoproteinproduktion |
| EP3215604A4 (en) * | 2014-10-27 | 2018-07-25 | Agency For Science, Technology And Research | Methods of recombinant protein expression in a cell comprising reduced udp-galactose transporter activity |
| LT3227454T (lt) | 2014-12-01 | 2020-07-27 | Amgen Inc. | Glikoproteino glikano sudedamosios dalies kiekio keitimo procedūra |
-
2015
- 2015-12-01 LT LTEP15816598.5T patent/LT3227454T/lt unknown
- 2015-12-01 SG SG10202002458PA patent/SG10202002458PA/en unknown
- 2015-12-01 ES ES15816598T patent/ES2784503T3/es active Active
- 2015-12-01 SG SG11201704351WA patent/SG11201704351WA/en unknown
- 2015-12-01 EA EA202091598A patent/EA202091598A3/ru unknown
- 2015-12-01 JP JP2017547931A patent/JP6698681B2/ja active Active
- 2015-12-01 EA EA201791223A patent/EA036178B1/ru not_active IP Right Cessation
- 2015-12-01 PT PT158165985T patent/PT3227454T/pt unknown
- 2015-12-01 KR KR1020177016893A patent/KR102623965B1/ko active Active
- 2015-12-01 PL PL15816598T patent/PL3227454T3/pl unknown
- 2015-12-01 WO PCT/US2015/063271 patent/WO2016089919A1/en not_active Ceased
- 2015-12-01 CA CA2969225A patent/CA2969225C/en active Active
- 2015-12-01 IL IL276165A patent/IL276165B/en unknown
- 2015-12-01 MX MX2017006997A patent/MX385409B/es unknown
- 2015-12-01 US US15/529,950 patent/US10167492B2/en active Active
- 2015-12-01 DK DK15816598.5T patent/DK3227454T3/da active
- 2015-12-01 CN CN201580071982.6A patent/CN107109455B/zh active Active
- 2015-12-01 EP EP20154019.2A patent/EP3680344A1/en active Pending
- 2015-12-01 SI SI201531140T patent/SI3227454T1/sl unknown
- 2015-12-01 HU HUE15816598A patent/HUE049201T2/hu unknown
- 2015-12-01 AU AU2015355087A patent/AU2015355087C1/en active Active
- 2015-12-01 EP EP15816598.5A patent/EP3227454B1/en not_active Revoked
-
2017
- 2017-05-29 IL IL252569A patent/IL252569B/en active IP Right Grant
- 2017-05-29 CL CL2017001369A patent/CL2017001369A1/es unknown
- 2017-05-31 ZA ZA2017/03729A patent/ZA201703729B/en unknown
-
2018
- 2018-11-14 US US16/191,352 patent/US20190085370A1/en not_active Abandoned
-
2020
- 2020-02-05 US US16/783,117 patent/US10822630B2/en active Active
- 2020-03-31 AU AU2020202302A patent/AU2020202302A1/en not_active Abandoned
- 2020-04-07 CY CY20201100325T patent/CY1123247T1/el unknown
- 2020-04-30 JP JP2020080270A patent/JP7066775B2/ja active Active
- 2020-09-29 ZA ZA2020/06002A patent/ZA202006002B/en unknown
- 2020-10-02 US US17/062,199 patent/US20210017565A1/en not_active Abandoned
-
2022
- 2022-01-28 AU AU2022200586A patent/AU2022200586A1/en not_active Abandoned
- 2022-04-26 JP JP2022072126A patent/JP2022101669A/ja active Pending
-
2023
- 2023-01-18 US US18/156,025 patent/US20230159974A1/en not_active Abandoned
-
2024
- 2024-04-10 JP JP2024063188A patent/JP2024095777A/ja active Pending
- 2024-06-24 AU AU2024204313A patent/AU2024204313A1/en not_active Abandoned
-
2025
- 2025-09-01 AU AU2025223948A patent/AU2025223948A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538446A5 (OSRAM) | ||
| IL310968B1 (en) | Mammalian cell culture | |
| Matanguihan et al. | Upstream continuous processing: recent advances in production of biopharmaceuticals and challenges in manufacturing | |
| JP2009502167A5 (OSRAM) | ||
| RU2009139054A (ru) | ПРИМЕНЕНИЕ НИЗКОЙ ТЕМПЕРАТУРЫ И/ИЛИ НИЗКОГО pН В КУЛЬТУРЕ КЛЕТОК | |
| EP4148121A3 (en) | Cell-controlled perfusion in continuous culture | |
| RU2013152982A (ru) | Способ снижения гетерогенности антител и способ получения соответствующих антител | |
| JP2010110331A5 (OSRAM) | ||
| JP2012519485A5 (OSRAM) | ||
| TW202328427A (zh) | 超高密度細胞儲存方法 | |
| CN116083344A (zh) | 对连续流动搅拌釜反应器细胞培养系统的连接灌注 | |
| CN103320390A (zh) | 一种大规模哺乳动物工程细胞培养方法 | |
| CN103773741A (zh) | 笼式通气搅拌生物反应器制备流感疫苗的方法 | |
| CN102382794B (zh) | 一种哺乳动物细胞的灌流培养方法 | |
| WO2021008571A1 (zh) | 高密度连续接种的细胞培养方法及其应用 | |
| CN106222129A (zh) | 一种提高抗体纯度的细胞培养基和培养方法 | |
| CN107299078A (zh) | 一株适应全悬浮培养的猫肾细胞系f‑81 s及其应用 | |
| CN104206173B (zh) | 一种利用野生猴头菇袋料栽培的方法 | |
| IL307155B2 (en) | Antibodies with modulated glycan profiles | |
| CN109628407A (zh) | 高密度长期培养表达抗vegf人源化单克隆抗体重组cho细胞的方法 | |
| CN109134645A (zh) | 一种细胞浓缩补料培养工艺 | |
| WO2018018613A1 (zh) | 一种提高抗体纯度的细胞培养基和培养方法 | |
| CN101838661B (zh) | 一种高稳定性藻蓝蛋白类融合荧光蛋白质的制备方法 | |
| CN109988803A (zh) | 一种高效生产重组人血清白蛋白的发酵方法 | |
| CN102776260B (zh) | 一种高效表达重组人凝血八因子的方法 |